首页> 外国专利> Use of 1-pyridylamino-indole derivatives for treating stress, or mixed, urinary incontinence, activate alpha-adrenergic receptors and inhibit norepinephrine recapture

Use of 1-pyridylamino-indole derivatives for treating stress, or mixed, urinary incontinence, activate alpha-adrenergic receptors and inhibit norepinephrine recapture

机译:1-吡啶基氨基吲哚衍生物用于治疗压力或混合性尿失禁的用途,激活α-肾上腺素能受体并抑制去甲肾上腺素的重新捕获

摘要

Use of 1-(pyridylamino)indole derivatives (I) for preparing a composition for treatment of stress, or mixed, urinary incontinence. 1-(Pyridylamino)indole derivatives of formula (I) and their salts are used for preparing a composition for treatment of stress, or mixed, urinary incontinence. R = hydrogen, alkyl, alkylene, alkylidyne, cycloalkyl, cycloalkylene, cycloalkylidyne, C(O)NH 2, C(O)R' or C(O)OR' (all optionally substituted and/or interrupted by O, C(O)O, OC(O), NHC(O) or C(O)NH); and R' = alkyl, alkylene, alkylidyne, cycloalkyl, cycloalkylene or cycloalkylidyne, all optionally substituted and/or interrupted as for R. [Image] ACTIVITY : Uropathic. MECHANISM OF ACTION : Activation of alpha -adrenergic receptors and selective inhibition of norepinephrine recapture. Segments of cleaned, isolated rabbit ureter were immersed in Krebs-Henseleit solution containing agents that blocked beta -adrenergic receptors, cathechol-O-methyltransferase and recapture of noradrenaline types 1 and 2, then equilibrated under a tension of 1 g. Segments that showed contractile response at least 1 g when contacted with norepinephrine (NE; 30 mu M) were then treated with indol-1-yl-pyridin-4-yl-amine salicylate. This compound induced significant contraction, e.g. when added at 10 -5 M it caused a contraction equal to about 35% of the contraction induced by a second application of NE (30 mu M).
机译:1-(吡啶基氨基)吲哚衍生物(I)在制备用于治疗压力或混合性尿失禁的组合物中的用途。式(I)的1-(吡啶基氨基)吲哚衍生物及其盐用于制备用于治疗压力或混合性尿失禁的组合物。 R =氢,烷基,亚烷基,亚烷基,环烷基,亚环烷基,亚环烷基,C(O)NH 2,C(O)R'或C(O)OR'(全部可选地被O,C(O )O,OC(O),NHC(O)或C(O)NH); R 1 =烷基,亚烷基,亚烷基,亚环炔基,环烷基,亚环烷基或亚环烷基,与R 1一样全部被取代和/或间断。作用机理:激活α-肾上腺素受体并选择性抑制去甲肾上腺素夺回。将清洁的分离的兔输尿管段浸入含有阻断β-肾上腺素能受体,胆甾醇-O-甲基转移酶并捕获1和2型去甲肾上腺素的药物的Krebs-Henseleit溶液中,然后在1 g张力下平衡。与去甲肾上腺素(NE; 30μM)接触时显示收缩反应至少1 g的片段,然后用吲哚-1-基吡啶4胺水杨酸酯处理。该化合物引起明显的收缩,例如收缩。当以10 -5> M加入时,它引起的收缩约等于第二次施用NE(30μM)引起的收缩的35%。

著录项

  • 公开/公告号NO20082254L

    专利类型

  • 公开/公告日2008-05-16

    原文格式PDF

  • 申请/专利权人 UROGENE;

    申请/专利号NO20080002254

  • 发明设计人 BIENAYME HUGUES;FERTE JACQUES;

    申请日2008-05-16

  • 分类号A61K31/4439;A61P13/10;

  • 国家 NO

  • 入库时间 2022-08-21 20:06:45

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号